← FDA DRUG APPROVALS

FDA NDA · NDA021988

Lamivudine/Zidovudine 150 mg/300 mg Tablets Co-packaged with Nevirapine 200 mg Tablets

Sponsor: STRIDES ACROLAB

APPLICATION
NDA021988
TYPE
NDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)

Products

Lamivudine/Zidovudine 150 mg/300 mg Tablets Co-packaged with Nevirapine 200 mg TabletsNone (Tentative Approval)
LAMIVUDINE 150MG, ZIDOVUDINE 300MG, NEVIRAPINE 200MG · TABLET · ORAL

Approval history

2007-03-02Type 4 - New Combination · Original · priorityLetterTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →